S E Pinder

Summary

Affiliation: King's College London
Country: UK

Publications

  1. ncbi Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation
    Sarah E Pinder
    Breast Research Pathology, Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, London, UK
    Mod Pathol 23:S8-13. 2010
  2. ncbi A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
    S E Pinder
    King s College London, Division of Cancer Studies, Research Oncology, 3rd Floor, Bermondsey Wing, Guy s Hospital, Great Maze Pond, London SE1 9RT, UK
    Br J Cancer 103:94-100. 2010
  3. ncbi The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example
    Sarah E Pinder
    Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, Great Maze Pond, London, UK
    J Clin Pathol 66:169-77. 2013
  4. ncbi Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
    R R Millis
    Hedley Atkins Cancer Research UK Breast Pathology Laboratory, Guy s Hospital, London SE1 9RT, UK
    Br J Cancer 90:1538-42. 2004
  5. ncbi Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003

Detail Information

Publications5

  1. ncbi Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation
    Sarah E Pinder
    Breast Research Pathology, Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, London, UK
    Mod Pathol 23:S8-13. 2010
    ..No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date...
  2. ncbi A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
    S E Pinder
    King s College London, Division of Cancer Studies, Research Oncology, 3rd Floor, Bermondsey Wing, Guy s Hospital, Great Maze Pond, London SE1 9RT, UK
    Br J Cancer 103:94-100. 2010
    ..Cases in the UKCCCR/ANZ DCIS trial have been histologically reviewed to determine the features of prognostic importance...
  3. ncbi The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example
    Sarah E Pinder
    Research Oncology, Division of Cancer Studies, King s College London, Guy s Hospital, Great Maze Pond, London, UK
    J Clin Pathol 66:169-77. 2013
    ..We make some suggestions regarding these challenges, and propose a checklist of features that should be considered in order to stimulate debate and improve the quality of data produced by TMA analysis...
  4. ncbi Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast
    R R Millis
    Hedley Atkins Cancer Research UK Breast Pathology Laboratory, Guy s Hospital, London SE1 9RT, UK
    Br J Cancer 90:1538-42. 2004
    ..This is in agreement with immunohistochemical and molecular data indicating that low-grade and high-grade mammary carcinomas are quite different lesions...
  5. ncbi Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres
    M Dowsett
    Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK
    J Pathol 199:418-23. 2003
    ..These data support an algorithm in which FISH testing is restricted to IHC 2+ tumours in reference centres. The results may not extrapolate to laboratories with less experience or using different methodologies...